0001439222-20-000008.txt : 20200218
0001439222-20-000008.hdr.sgml : 20200218
20200218160533
ACCESSION NUMBER: 0001439222-20-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200213
FILED AS OF DATE: 20200218
DATE AS OF CHANGE: 20200218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bowden Christopher
CENTRAL INDEX KEY: 0001608601
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 20625279
MAIL ADDRESS:
STREET 1: 38 SIDNEY STREET, 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20080703
4
1
wf-form4_158205991627413.xml
FORM 4
X0306
4
2020-02-13
0
0001439222
AGIOS PHARMACEUTICALS, INC.
AGIO
0001608601
Bowden Christopher
C/O AGIOS PHARMACEUTICALS, INC.
88 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common stock
2020-02-13
4
M
0
7100
35.16
A
8750
D
Common stock
2020-02-13
4
S
0
7100
50.1566
D
1650
D
Stock option (right to buy)
35.16
2020-02-13
4
M
0
7100
0
D
2024-05-30
Common stock
7100.0
19306
D
This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.82. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.
/s/ William Cook, as Attorney-in-fact for Christopher Bowden
2020-02-18